MLND has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MLND has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
Millendo Therapeutics's Capital Expenditure for the three months ended in Mar. 2021 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2021 was $0.00 Mil.
GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.
The historical data trend for Millendo Therapeutics's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Millendo Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | |||||||||||
Capex-to-Revenue | Get a 7-Day Free Trial | 3.96 | 0.54 | - | - | - |
Millendo Therapeutics Quarterly Data | ||||||||||||||||||||
Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | |
Capex-to-Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Millendo Therapeutics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Millendo Therapeutics's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where Millendo Therapeutics's Capex-to-Revenue falls into.
Millendo Therapeutics's Capex-to-Revenue for the fiscal year that ended in Dec. 2020 is calculated as
Capex-to-Revenue | = | - Capital Expenditure | / | Revenue |
= | - (-0.026) | / | 0 | |
= | N/A |
Millendo Therapeutics's Capex-to-Revenue for the quarter that ended in Mar. 2021 is calculated as
Capex-to-Revenue | = | - Capital Expenditure | / | Revenue |
= | - (0) | / | 0 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Millendo Therapeutics (NAS:MLND) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
Thank you for viewing the detailed overview of Millendo Therapeutics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Mary Lynne Hedley | director | C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451 |
Howe John P Md | director | C/O BB&T, P O BOX 1250, WINSTON SALEM NC 27102-1250 |
Carol Giltner Gallagher | director | C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Habib J Dable | director | C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139 |
Carole Nuechterlein | director | C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015 |
Geoffrey Nichol | director | MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540 |
James M. Hindman | director | 2525 DUPONT DRIVE, IRVINE CA 92612 |
Christophe Arbet-engels | officer: Chief Medical Officer | C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104 |
Ryan Zeidan | officer: Chief Development Officer | C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104 |
Julia C. Owens | director, officer: President and CEO | C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451 |
Tamara L Joseph | officer: General Counsel and Secretary | 32 GARRISON STREET, APT 50-103, BOSTON MA 02116 |
Arcudi Iii Louis J | officer: Chief Financial Officer | C/O IDERA PHARMACEUTICALS 167 SYDNEY ST, CAMBRIDGE MA 02139 |
Randall W Whitcomb | director | 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807 |
Jeffery M. Brinza | officer: Sec., CAO and General Counsel | C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451 |
Pharis Mohideen | officer: Chief Medical Officer | C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451 |
From GuruFocus
By PRNewswire PRNewswire • 05-06-2021
By Business Wire Business Wire • 06-23-2020
By Marketwired Marketwired • 06-22-2021
By Business Wire Business Wire • 09-24-2020
By Business Wire Business Wire • 08-10-2020
By Marketwired Marketwired • 06-09-2021
By Barry Cohen Barry Cohen • 09-27-2020
By Business Wire Business Wire • 08-05-2020
By TipRanks TipRanks • 01-20-2015
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.